Event
BIOE Seminar Series: Casey Maguire (Harvard Medical School/Mass General Hospital)
Friday, October 30, 2020
Virtual
Steven Jay
smjay@umd.edu
Join us for the Bioengineering Seminar Series, which connects experts from around the country with our faculty, students, and staff to discuss their recent findings. Everyone is welcome!
The Fall 2020 seminars will be held virtually on Fridays from 9:00 a.m. – 9:50 a.m., unless otherwise noted. All BIOE faculty, students, staff, postdocs, and affiliates as well as additional subscribers to our weekly seminars emails will receive Zoom event information the week of each seminar.
If you do not yet receive our weekly seminars email and would like to subscribe to the listserv, or if there is a particular seminar listed below that you would like to attend, please email Emily Rosenthal.
Strategies for in vivo barriers to gene therapy vectors
Gene therapy to treat human disease has evolved from a relatively small group of dedicated scientists working on the fundamentals of gene delivery to mammalian cells, to a large industry capable of ex-vivo and in vivo gene therapy in patients. While many promising delivery systems exist or are being developed, adeno-associated virus (AAV) vectors are currently the most tested and most efficient vehicle for in vivo human gene therapy. Clinical efficacy has been achieved for several indications, and FDA-approved AAV-based medicines are on the market. As in every area of medicine, lessons learned from preclinical and clinical data drive technological innovation of AAV vectors. This webinar will focus on our experiences with novel AAV vectors to overcome some of these challenges, which include inefficient delivery to target organs and immune evasion. Specifically, the use of improved AAV library systems, AAV capsid repurposing, and the use of extracellular vesicles to enhance desired vector properties will be covered.
